Sign in
RNAZ Stock Price, Chart, Stats & News
TransCode Therapeutics, Inc.
Save
4.75M
Market cap
–
Current P/E
–
Forward P/E
RNAZ chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -519.14% |
ROE | -684.86% |
D/E | – |
Interest coverage ratio | -2156.07x |
RNAZ valuation
P/E | – |
P/S | – |
P/B | 5.09x |
P/CF | -0.50x |
P/FCF | -0.55x |
P/OCF | -0.50x |
PEG | 0.01x |
EV multiple | -0.40x |
About
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B.
Similar securities
Based on sector and market capitalization
Report issue